Myopia or near sightedness is a growing global health concern with industry experts predicting nearly 50% of the world’s population to be impacted by 2050.3 “The strategic partnership with Haag-Streit aligns with one of HOYA Vision Care’s core missions to provide information and innovative solutions to our valued ECP’s who are on the front lines as we globally address the rapidly growing problem of myopia in children,” said Alexandre Montague, CEO, HOYA Vision Care.
“By bringing together our organizations technologies and solutions we are creating a seamless approach for our ECP business partners to expand their myopia management capabilities and tackle this growing global epidemic.”
Thomas Bernhard, CEO of Haag-Streit Group added, "Haag-Streit is pleased to enter into this strategic partnership with HOYA Vision Care, which provides ECPs with an end-to-end and comprehensive package that optimally equips them to combat myopia. We are convinced that with this seamless intersection of the LENSTAR Myopia by HOYA and the MiYOSMART spectacle lens treatment protocol, we can together make a valuable contribution to combating the worldwide progression of myopia."
This agreement creates preferred partner status between the two companies to provide diagnostics and treatment for myopia to as many ECPs as possible as myopia continues to rise around the globe. Currently, LENSTAR Myopia is being utilized by HOYA ECPs in China with planned distribution expansion into APAC, EMEA and Canada in the near future.
PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.
1 Holden B. A. et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-1042
2 Hoya data on file - July21
3Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739